Compare Grab Holdings Ltd. (GRAB) vs Oscar Health Inc (OSCR) Price & Performance

GRAB trades at $3.19, up 3.57% today, with a bearish technical signal but strong fundamental momentum. The company has delivered three consecutive quarterly EPS beats, with Q2 2026 revenue up 22% year-over-year to $997 million. Recent news highlights a $1.49 billion acquisition of a majority stake in Atome Financial and a $30 million CEO share purchase, signaling confidence in growth. Cash flow trends show volatility, with 2025 net cash flow positive at $469 million but a projected decline to -$1.0 billion in 2026.

The outlook for GRAB is supported by robust revenue growth, expanding profitability, and aggressive financial services expansion, but risks include high capital expenditure, competitive pressures in Southeast Asia, and potential regulatory scrutiny. Analyst consensus is strongly bullish with 91.67% buy ratings, though technical indicators suggest near-term caution. The stock's valuation at a P/E of 28.27 reflects growth expectations but requires sustained execution to justify.

OSCR trades at $33.41, up 1.52% today, with a bullish technical signal and strong recent earnings beats in Q1 and Q2 2026. The stock shows robust revenue growth, with 2026 revenue projected at $15.3B and a return to profitability. Analyst sentiment is mixed but leans positive, with a consensus price target of $34.00. Recent news highlights market share gains and raised 2026 guidance, though the stock faces tests from rising medical costs.

The outlook is cautiously optimistic, driven by scalable growth in the ACA market and margin expansion opportunities. Key risks include medical cost pressures and competitive threats. Upside potential exists if the company executes on its 2029 EPS target of $4+, but investors should monitor profitability sustainability amid cost headwinds.